Patents Represented by Attorney Palaiyur S. Kalyanaraman

Find this attorney in the Justia Lawyer Directory

  • N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
    Patent number: 7807683
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: October 5, 2010
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Ronald J. Doll, Viyyoor M. Girijavallabhan, Alan Mallams, Carmen S. Alvarez, Kartik M. Keertikar, Jocelyn Rivera, Tin Yau Chan, Vincent Madison, Thierry O. Fischmann, Lawrence W. Dillard, Vinh D. Tran, Zhen Min He, Ray Anthony James, Haengsoon Park, Vidyadhar M. Paradkar, Douglas Walsh Hobbs
  • Piperazine-piperidines with CXCR3 antagonist activity
    Patent number: 7763616
    Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: July 27, 2010
    Assignee: Schering Corporation
    Inventors: Wensheng Yu, Seong Heon Kim, Gopinadhan N. Anilkumar, Stuart B. Rosenblum, Bandarpalle B. Shankar, Brian F. McGuinness, Douglas W. Hobbs, Yuefei Shao
  • Compounds as inhibitors of hepatitis C virus NS3 serine protease
    Patent number: 7759499
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: July 20, 2010
    Assignee: Schering Corporation
    Inventors: Srikanth Venkatraman, F. George Njoroge, Melissa L. Blackman, Wanil Wu, Latha G. Nair, Ashok Arasappan, Stephane L. Bogen, Kevin X. Chen, Mousumi Sannigrahi, Frank Bennett, Viyyor M. Girijavallabhan
  • Compounds as inhibitors of hepatitis C virus NS3 serine protease
    Patent number: 7718691
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: May 18, 2010
    Assignee: Schering Corporation
    Inventors: Srikanth Venkatraman, F. George Njoroge, Melissa L. Blackman, Wanil Wu, Latha G. Nair, Ashok Arasappan, Stephane L. Bogen, Kevin X. Chen, Mousumi Sannigrahi, Frank Bennett, Viyyor M. Girijavallabhan
  • Bipiperdine derivatives useful as CCR3 antagonists
    Patent number: 7705153
    Abstract: The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.
    Type: Grant
    Filed: February 2, 2005
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventors: Pauline C. Ting, Jianhua Cao, Youhao Dong, Eric J. Gilbert, Ying Huang, Joseph M. Kelly, Stuart McCombie, Neng-Yang Shih
  • Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
    Patent number: 7645762
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: January 12, 2010
    Assignee: Schering Corporation
    Inventors: Kamil Paruch, Timothy J. Guzi, Michael P. Dwyer
  • Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
    Patent number: 7642266
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a] pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: January 5, 2010
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer
  • Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
    Patent number: 7635694
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: December 22, 2009
    Assignee: Schering Corporation
    Inventors: Stephane L. Bogen, Weidong Pan, Sumie Ruan, F. George Njoroge
  • Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus
    Patent number: 7619094
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: November 17, 2009
    Assignee: Schering Corporation
    Inventors: Kevin X Chen, F George Njoroge, Mousumi Sannigrahi, Latha G Nair, Weiying Yang, Bancha Vibulbhan, Srikanth Venkatraman, Ashok Arasappan, Stephane L. Bogen, Frank Bennett, Viyyoor M. Girijavallabhan
  • Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
    Patent number: 7605155
    Abstract: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 20, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Kartik M. Keertikar
  • Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
    Patent number: 7601724
    Abstract: In its many embodiments, the present invention provides a class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: October 13, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer
  • Compounds for the treatment of inflammatory disorders
    Patent number: 7598242
    Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-? or combinations thereof.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: October 6, 2009
    Assignee: Schering Corporation
    Inventors: Zhaoning Zhu, Robert Mazzola, Zhuyan Guo, Brian J. Lavey, Lisa Sinning, Joseph Kozlowski, Brian McKittrick, Neng-Yang Shih
  • Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
    Patent number: 7592419
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula 1: wherein Z?, L?, M?, R1, X and D are defined herein.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: September 22, 2009
    Assignee: Schering Corporation
    Inventors: Srikanth Venkatraman, F. George Njoroge, Wanli Wu, Viyyoor M. Girijavallabhan, Brian McKittrick, Jing Su, Francisco Velazquez, Patrick A. Pinto
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent number: 7592316
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: September 22, 2009
    Assignee: Schering Corporation
    Inventors: F. George Njoroge, Ashok Arasappan, Srikanth Venkatraman, Stephane L. Bogen, Kevin X. Chen, Frank Bennett
  • Imidazopyrazines as cyclin dependent kinase inhibitors
    Patent number: 7576085
    Abstract: In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: August 18, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Lianyun Zhao, Patrick J. Curran, David B. Belanger, Blake Hamann, Panduranga A. Reddy, M. Arshad Siddiqui
  • Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
    Patent number: 7563798
    Abstract: In its many embodiments, the present invention provides a class of pyrazolo [1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases (CDKs), methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: July 21, 2009
    Assignee: Schering Corporation
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, M. Arshad Siddiqui, Panduranga Adulla P. Reddy, David B. Belanger, Blake Hamann, Patrick J. Curran
  • Imidazopyrazines as protein kinase inhibitors
    Patent number: 7557104
    Abstract: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: June 5, 2007
    Date of Patent: July 7, 2009
    Assignee: Schering Corporation
    Inventors: Lianyun Zhao, Panduranga Adulla P. Reddy, Neng-Yang Shih, Kamil Paruch, Timothy J. Guzi, M. Arshad Siddiqui
  • Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7550467
    Abstract: The present invention discloses compounds of Formula I wherein V, W, Y, Z, R1, R2, R3, R4, d, m, n, p and r are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: June 23, 2009
    Assignee: Schering Corporation
    Inventors: Tao Guo, Huizhong Gu, Douglas Walsh Hobbs
  • Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
    Patent number: 7550559
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: June 23, 2009
    Assignee: Schering Corporation
    Inventors: Mousumi Sannigrahi, F. George Njoroge, Viyyoor M. Girijavallabhan
  • Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
    Patent number: 7514442
    Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: April 7, 2009
    Assignees: Schering Corporation, Pharmacopeia, Inc.
    Inventors: Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Ronald J. Doll, Viyyoor M. Girijavallabhan, Carmen S. Alvarez, Tin Yau Chan, Chad Knutson, Vincent Madison, Thierry O. Fischmann, Lawrence W. Dillard, Vinh D. Tran, Zhen Min He, Ray Anthony James, Haengsoon Park